Skip to main content
SpringerLink
Log in

Exploring Big Data in Hematological Malignancies: Challenges and Opportunities

  • Health Economics (N Khera, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Secondary analysis of large datasets has become a useful alternative to address research questions outside the reach of clinical trials. It is increasingly utilized in hematology and oncology. In this review, we provided an overview of some examples of commonly used large datasets in the USA and described common research themes that can be pursued using such a methodology. We selected a sample of 14 articles on adult hematologic malignancies published in 2015 and highlighted their contributions as well as limitations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Call TG et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc. 1994;69(4):323–8.

    Article  CAS  PubMed  Google Scholar 

  2. Shanafelt TD, Gunderson H, Call TG. Commentary: chronic lymphocytic leukemia—the price of progress. Oncologist. 2010;15(6):601–2.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Shanafelt TD et al. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract. 2015;11(3):252–8.

    Article  PubMed  Google Scholar 

  4. Pasquini MC, Z.X. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2015. Available at: http://www.cibmtr.org.

  5. Winn AN et al. The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma. Journal of the National Cancer Institute. 2015;107(8):djv139. doi:10.1093/jnci/djv139.

  6. Shah GL et al. Cost-effectiveness of autologous hematopoietic stem cell transplantation for elderly patients with multiple myeloma using the surveillance, epidemiology, and end results—Medicare database. Biol Blood Marrow Transplant. 2015;21(10):1823–9. SEER-based study showed that autologous HSCT is cost-effective when compared to non-transplantation care in elderly patients with MM.

    Article  PubMed  Google Scholar 

  7. Hoppe RT, A.R., Bierman PJ et al, Hodgkin disease/lymphoma: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2015;13(5):554–86.

  8. Siegel R, D.C., Virgo K et al. Cancer treatment and survivorship statistics, 2012. Cancer J Clin, 2012. 62: 220–241.

  9. Franklin J et al. Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomised trials. Ann Oncol. 2006;17(12):1749–60.

    Article  CAS  PubMed  Google Scholar 

  10. Aleman BM et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878–86.

    Article  CAS  PubMed  Google Scholar 

  11. Canellos GP et al. Treatment of favorable, limited-stage Hodgkin’s lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol. 2010;28(9):1611–5.

    Article  PubMed  Google Scholar 

  12. Herbst C et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica. 2010;95(3):494–500.

    Article  CAS  PubMed  Google Scholar 

  13. Meyer RM et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366(5):399–408.

    Article  CAS  PubMed  Google Scholar 

  14. Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base. J Clin Oncol. 2015;33(6):625–33. Population study utilizing the NCDB database showed evidence suggesting that CMT abandonment can be detrimental in early stage HL survival.

    Article  PubMed  Google Scholar 

  15. Attal M et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med. 1996;335(2):91–7.

    Article  CAS  PubMed  Google Scholar 

  16. Lenhoff S et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 2000;95(1):7–11.

    CAS  PubMed  Google Scholar 

  17. Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia. 2014;28(6):1346–8.

    Article  CAS  PubMed  Google Scholar 

  18. Turesson I et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol. 2010;28(5):830–4.

    Article  PubMed  Google Scholar 

  19. Vij R et al. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2015;21(2):335–41.

    Article  PubMed  Google Scholar 

  20. Costa LJ, Gonsalves WI, Kumar SK. Early mortality in multiple myeloma. Leukemia. 2015;29(7):1616–8.

    Article  CAS  PubMed  Google Scholar 

  21. Sanchorawala V et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood. 2015;126(20):2345–7.

    Article  PubMed  Google Scholar 

  22. Jaccard A et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. New Engl J Med. 2007;357(11):1083–93.

    Article  CAS  PubMed  Google Scholar 

  23. Gertz MA et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48(4):557–61.

    Article  CAS  PubMed  Google Scholar 

  24. D'Souza A et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research study. J Clin Oncol. 2015;33(32):3741–9. Utilizing data from the CIBMTR the authors demonstrated that in recent years post-transplantation mortality in AL significantly improved, and center expertise with AL transplantation was important in reducing early mortality.

    Article  PubMed  Google Scholar 

  25. Go RS. Monoclonal gammopathy of undetermined significance: to screen or not to screen for multiple myeloma? Br J Haematol. 2010;149(4):620–1. Author reply 621-3.

    Article  PubMed  Google Scholar 

  26. Go RS, Gundrum JD, Neuner JM. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Clin Lymphoma Myeloma Leuk. 2015;15(3):177–86. e4.

    Article  PubMed  Google Scholar 

  27. Feugier P et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117–26.

    Article  CAS  PubMed  Google Scholar 

  28. SEER cancer statistics factsheets: non-Hodgkin lymphoma. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/nhl.html.

  29. Odejide OO, et al. Hospice use among patients with lymphoma: impact of disease aggressiveness and curability. J Natl Cancer Inst. 2016. 108(1).

  30. Ferreri AJ et al. Enteropathy-associated T-cell lymphoma. Crit Rev Oncol Hematol. 2011;79(1):84–90.

    Article  PubMed  Google Scholar 

  31. Karanam PK, Al-Hamadani M, Go RS. Enteropathy-associated T-cell lymphoma in the US: higher incidence and poorer survival among Asians. Br J Haematol. 2015.

  32. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med. 2002;137(6):511–20.

    Article  PubMed  Google Scholar 

  33. Giri S et al. Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia: a matched cohort study. Blood. 2015;125(21):3359–60.

    Article  CAS  PubMed  Google Scholar 

  34. National Cancer Institute. SEER stat fact sheets: acute myeloid leukemia. Bethesda, MD:. Available from URL: http://seer.cancer. gov/statfacts/html/amyl.html. 2013 [cited 2015 February].

  35. Medeiros BC et al. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015;94(7):1127–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Smith A et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Pfreundschuh M et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–91.

    Article  CAS  PubMed  Google Scholar 

  38. Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.

    Article  CAS  PubMed  Google Scholar 

  39. Williams JN et al. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer. 2015;121(11):1800–8. Largest study to date evaluating treatment patterns and outcomes in patients with DLBCL aged >80 years showed that elderly patients treated with R-CHOP had the longest survival, however, were less likely to receive this treatment combination when compared to younger patients.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Rubin DB. Matching to remove bias in observational studies. Biometrics 29.1 (1973): 159–183. Web…

  41. Bender R. Introduction to the use of regression models in epidemiology. Methods Mol Biol. 2009;471:179–95.

    Article  PubMed  Google Scholar 

  42. Ross ME et al. Propensity score methods for analyzing observational data like randomized experiments: challenges and solutions for rare outcomes and exposures. Am J Epidemiol. 2015;181(12):989–95.

    Article  PubMed  Google Scholar 

  43. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 Pt 2):757–63.

    Article  CAS  PubMed  Google Scholar 

  44. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29(6):1102.

    Article  PubMed  Google Scholar 

  45. Sledge GW Jr, Miller RS, Hauser R. CancerLinQ and the future of cancer care. Am Soc Clin Oncol Educ Book. 2013. doi:10.1200/EdBook_AM.2013.33.430.

  46. Shah A et al. Building a rapid learning health care system for oncology: why CancerLinQ collects identifiable health information to achieve its vision. J Clin Oncol. 2016;34(7):756–63.

    Article  PubMed  Google Scholar 

  47. Kumar S et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood. 2011;118(7):1979–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Robbins AS et al. Association between the affordable care act dependent coverage expansion and cervical cancer stage and treatment in young women. JAMA. 2015;314(20):2189–91.

    Article  CAS  PubMed  Google Scholar 

  49. Zhu J et al. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA. 2012;307(15):1593–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Carroll NM et al. Use of bevacizumab in community settings: toxicity profile and risk of hospitalization in patients with advanced non-small-cell lung cancer. J Oncol Pract. 2015;11(5):356–62.

    Article  PubMed  Google Scholar 

  51. Ailawadhi S et al. Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups. Blood Cancer J. 2014;4:e243.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Pollack LA et al. Care of long-term cancer survivors: physicians seen by Medicare enrollees surviving longer than 5 years. Cancer. 2009;115(22):5284–95.

    Article  PubMed  Google Scholar 

  53. McWilliams JM et al. Geographic variation in cancer-related imaging: Veterans Affairs health care system versus Medicare. Ann Intern Med. 2014;161(11):794–802.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Pachman DR et al. Calcium and magnesium use for oxaliplatin-induced neuropathy: a case study to assess how quickly evidence translates into practice. J Natl Compr Canc Netw. 2015;13(9):1097–101.

    CAS  PubMed  Google Scholar 

  55. Greif JM et al. Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the National Cancer Data Base. Ann Surg Oncol. 2012;19(10):3199–204.

    Article  PubMed  Google Scholar 

  56. Gonsalves WI et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014;124(6):907–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Chagpar R et al. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol. 2012;30(9):972–9.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Charlton ME et al. Is travel time to colonoscopy associated with late-stage colorectal cancer among Medicare beneficiaries in Iowa? J Rural Health. 2015. doi:10.1111/jrh.12159.

  59. Dimick J et al. Black patients more likely than whites to undergo surgery at low-quality hospitals in segregated regions. Health Aff. 2013;32(6):1046–53.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Gustavo F. Westin, Ajoy L. Dias & Ronald S. Go

Authors
  1. Gustavo F. Westin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ajoy L. Dias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ronald S. Go
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald S. Go.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Health Economics

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Westin, G.F., Dias, A.L. & Go, R.S. Exploring Big Data in Hematological Malignancies: Challenges and Opportunities. Curr Hematol Malig Rep 11, 271–279 (2016). https://doi.org/10.1007/s11899-016-0331-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-016-0331-4

Keywords

Search

Navigation